Description:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>The aim of this study was to evaluate very long‐term results after unrestricted everolimus‐eluting bioresorbable scaffolds (BRS) implantation.</jats:p></jats:sec><jats:sec><jats:title>Background</jats:title><jats:p>Previous randomized studies mainly included selected patients differing from those seen during daily routine and long‐term data from all‐comers registries are sparse.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Consecutive patients undergoing BRS implantation were included in this observational, single center study. Clinical follow‐up was conducted up to 5 years. Endpoint of interest was the composite of target lesion failure (TLF), including target‐vessel myocardial infarction and target lesion revascularization and cardiac death. Furthermore, ARC‐defined scaffold thrombosis (ScT) were assessed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 176 patients with a median age of 64 (55 – 72) years were analyzed, of which 59.6% presented an acute coronary syndrome. A total of 183 mainly complex lesions (55.8%) were treated. At 5 years, the rate for TLF was 21.6%. Definite or probable ScT rate was 4.1%. The rate of ScT within the first year was 2.8% and afterwards 1.2%. Notably, no ScT was seen later than 2 years.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Although this real‐world registry displays high rates of clinical events during long‐term follow‐up, no ScT was seen after 2 years.</jats:p></jats:sec>